Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laparoscopic HIPEC for Gastric Carcinomatosis
NCT02092298Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2014
- Primary completion
- May 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c and Cisplatin micelle injection (HA132) in gastric cancer (GC) and gastroesophageal junction cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival After Hyperthermic Intraperitoneal Chemotherapy at 5 years and Overall Survival From the First Laparoscopic HIPEC at 5 years. Started May 2014; status: completed.
02
Drugs
mitomycin cCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02092298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092298.